Pembroke Pines, FL -- NextWave Research Initiates Coverage on NovaBay Pharmaceuticals (Amex:NBY) with a Strong Speculative Buy Rating and $4.50 Price Target. The complete research report is available free of charge at http://www.NextWaveResearch.com
The research report written by Stephen M. Dunn describes NovaBay Pharmaceuticals Aganocide® compounds that mimic the human body’s natural antimicrobial defenses generated within neutrophils (white blood cells). Aganocides® may deliver the same or better efficacy than antibiotics without triggering antibiotic-resistance.
Several catalysts for NovaBay shares are expected as various human clinical trials complete. Clinical results are expected for Conjunctivitis (“pink eye”) partnered with Alcon (NYSE:ACL), Acne and Impetigo partnered with Galderma S.A. (Nestle and L'Oreal) and Catheter-Associated Urinary Tract Infections (CAUTI) which is being developed internally. In addition, several new indications are expected to begin human clinical trials with partner Alcon for Otitis Media (middle-ear infection), Contact Lens Solution and Sinusitis (sinus infection) as well as NovaBay’s internal Onychomycosis (nail fungus) program.
Mr. Dunn states "I believe NovaBay represents a significant opportunity in the drug-resistant pathogen sector. Their Aganocide® compounds appear effective against bacterial, viral, fungal and biofilm targets without generating new, drug-resistant strains.” He further notes “NovaBay’s partnerships with Alcon and Galderma along with NovaBay’s own internal programs result in a biotechnology company with a surprising number of shots-on-goal.”
Interested investors can access the complete NovaBay Pharmaceuticals research report free-of-charge at http://www.NextWaveResearch.com
About NextWave Research:
NextWave Research was created to address the dearth of professional Wall Street research coverage for quality small-cap companies. We believe that quality companies who choose to sponsor research analyst coverage provide a desperately needed service to both individual and institutional investors with reports and commentary freely available to the public.
